CareDx Inc. (CDNA)
CareDx, Inc (CDNA) Q1 2025 Earnings Call Transcript
CareDx, Inc (NASDAQ:CDNA ) Q1 2025 Earnings Conference Call April 30, 2025 4:30 PM ET Company Participants Caroline Corner - Investor Relations John Hanna - President & Chief Executive Officer Robert Woodward - Chief Scientific Officer Abhishek Jain - Chief Financial Officer Keith Kennedy - Chief Operating Officer Conference Call Participants Mason Carrico - Stephens Brandon Couillard - Wells Fargo Thomas DeBourcy - Nephron Research Operator Good day, everyone, and welcome to today's CareDx First Quarter 2025 Earnings Conference Call. At this time, all participants are in a listen-only-mode.
CareDx (CDNA) Tops Q1 Earnings Estimates
CareDx (CDNA) came out with quarterly earnings of $0.09 per share, beating the Zacks Consensus Estimate of $0.06 per share. This compares to loss of $0.03 per share a year ago.
CareDx, Inc (CDNA) Q4 2024 Earnings Call Transcript
CareDx, Inc (NASDAQ:CDNA ) Q4 2024 Earnings Conference Call February 26, 2025 4:30 PM ET Company Participants Caroline Corner - Investor Relations John Hanna - President and Chief Executive Officer Abhishek Jain - Chief Financial Officer Conference Call Participants Mark Massaro - BTIG Bill Bonello - Craig-Hallum Andrew Cooper - Raymond James Mason Carrico - Stephens Eduardo Martinez - H.C. Wainwright Thomas DeBourcy - Nephron Research Operator Good afternoon, everyone.
CareDx (CDNA) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
Although the revenue and EPS for CareDx (CDNA) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
CareDx (CDNA) Soars 11.2%: Is Further Upside Left in the Stock?
CareDx (CDNA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Does CareDx (CDNA) Have the Potential to Rally 42.25% as Wall Street Analysts Expect?
The consensus price target hints at a 42.3% upside potential for CareDx (CDNA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Is CareDx (CDNA) Outperforming Other Medical Stocks This Year?
Here is how CareDx (CDNA) and DaVita HealthCare (DVA) have performed compared to their sector so far this year.
Strength Seen in CareDx (CDNA): Can Its 6.1% Jump Turn into More Strength?
CareDx (CDNA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
CareDx: Top Of My Shopping List For 2025
CareDx is a promising candidate for the Bioreactor growth portfolio due to its leadership in transplant diagnostics and significant growth potential despite previous concerns. The company has shown strong revenue growth, with Q3 2023 revenue up 23% YoY, and maintains a robust balance sheet with $241M in cash and no debt. Key risks include potential slow adoption by transplant centers, competition from major players like Natera, and macroeconomic factors affecting the transplant market.
Has CareDx (CDNA) Outpaced Other Medical Stocks This Year?
Here is how CareDx (CDNA) and Clover Health Investments, Corp. (CLOV) have performed compared to their sector so far this year.
Wall Street Analysts Predict a 49.89% Upside in CareDx (CDNA): Here's What You Should Know
The consensus price target hints at a 49.9% upside potential for CareDx (CDNA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
After Plunging -11.97% in 4 Weeks, Here's Why the Trend Might Reverse for CareDx (CDNA)
The heavy selling pressure might have exhausted for CareDx (CDNA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
